Impact of FCGR3A V158F and FCGR2A H131R variants on ofatumumab efficacy in DLBCL and CLL.

Sarah M. Glass,Pamela L. St. Jean,Kay Murphy,Louise Clapham,Eddie Carden,Astrid McKeown,Michele Gorczyca,Oliver Wright,Michael Fennessy,Ira V. Gupta,Colin F. Spraggs

Impact of FCGR3A V158F and FCGR2A H131R variants on ofatumumab efficacy in DLBCL and CLL.

2015

Sarah M. Glass
Pamela L. St. Jean
Kay Murphy
Louise Clapham
Eddie Carden
Astrid McKeown
Michele Gorczyca
Oliver Wright
Michael Fennessy
Ira V. Gupta
Colin F. Spraggs

e22085 Background: Ofatumumab is an anti-CD20 monoclonal antibody that induces cell lysis primarily through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC). Gi...

Keywords:

Oncology
Pathology
FCGR2A
Ofatumumab
FCGR3A
Internal medicine
Medicine
Cancer research
Lysis
Monoclonal antibody
Cytotoxicity
Antibody-dependent cell-mediated cytotoxicity
Cellular Cytotoxicity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations